Provider recommendations for human papillomavirus vaccine (HPV) among adolescent males in Southwest Georgia counties and the associated HPV prevalence in this population

Poku Benjamin; Christopher Cheryl

doi:10.30574/gscarr.2020.3.1.0023

Authors

Poku Benjamin MPH, Lecturer Master of Public Health, Eastern Washington University, Spokane Washington, USA
Christopher Cheryl MPA, Assistant Professor, Borough of Manhattan Community College, New York. USA

DOI:

https://doi.org/10.30574/gscarr.2020.3.1.0023

Keywords:

Human Papilloma Virus, HPV Vaccines, Rural Health, Cancer causing virus, Sexually transmitted virus

Abstract

The study examines variation of providers’ behavior in recommending the Human Papillomavirus (HPV) vaccine to young male adolescents (aged 11-12), middle male adolescents (aged 13-17) and late male adolescents (aged 18-26) in Southwest (SW) Georgia. Upon IRB approval, secondary data were obtained from Albany Area Primary Care for a paper-based survey that was conducted in 2014 using a representative random sample of family physicians (n=12), pediatricians (n=6), and nurse practitioners (n=33). The survey had a response rate of 76% and the researcher used descriptive statistics, t tests and ANOVA to describe the pediatricians’ (Peds), nurse practitioners’ (NPs), and family physicians’ (FPs) recommendations to HPV vaccinations in SW GA. Statistical analysis show barriers such as healthcare providers’ and parents’ discomfort with the vaccination of pre-teens when it concerns a sexually transmitted disease, lack of awareness to the role that males play in the spread of HPV, absence of government mandates, and non-completion of the three-dose series of vaccination due to financial or logistical reasons. Provider specialty, age, ethnicity, and reported barriers were significantly associated with recommendations and association to HPV prevalence. Policy level intervention, perceived barriers and support to HPV vaccination to providers may drive decisions about HPV vaccine uptake and completion of vaccination series.

Metrics

Metrics Loading ...

References

AbouZ C and Boerma T. (2005). Health information systems: the foundations of public health. Bulletin of the World Health Organization, 83, 578-583.

Adams M, Jasani B and Fiander A. (2007). Human papillomavirus (HPV) prophylactic vaccination: Challenges for public health and implications for screening. Vaccine, 25, 3007–3013.

Adinoff, B, Conley RR, Taylor SF and Chezem LL. (2013). Protecting confidentiality in human research. American Journal of Psychiatry, 170(5), 466–470.

Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE and Guy RJ. (2013). Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ, 346.

Allen JD, Othus MK, Shelton RC, Li Y, Norman N, Tom L and Del Carmen MG. (2010). Parental decision making about the HPV vaccine. Cancer Epidemiology Biomarkers & Prevention, 19(9), 2187–2198.

Bandura A. (2001). Social cognitive theory: An agentic perspective. Annu. Rev. Psychol., 52, 1-26.

Baral S, Logie CH, Grosso A, Wirtz AL and Beyrer, C. (2013). Modified social ecological model: a tool to guide the assessment of the risks and risk contexts of HIV epidemics. BMC Public Health, 13(482), 1-8.

Bartolini RM, Winkler JL, Penny ME and LaMontagne DS. (2012). Parental acceptance of HPV vaccine in Peru: A decision framework. PLoS ONE, 7(10), e48017.

Bastani R, Glenn B, Tsui J, Chang LC, Marchand E, Taylor VM and Singhal R. (2011). Understanding sub-optimal HPV vaccine uptake among ethnic minority girls. Cancer Epidemiol Biomarkers Prev, 20(7), 1463-1472.

Borrayo A and Jenkins R. (2003). Feeling frugal: Socioeconomic status, acculturation, and cultural health beliefs among women of Mexican descent. Cultural Diversity and Ethnic Minority Psychology, 9(2), 197–206.

Brankovic I, Verdonk P and Klinge I. (2013). Applying a gender lens on human papillomavirus infection: cervical cancer screening, HPV DNA testing, and HPV vaccination. International Journal for Equity in Health, 12(14).

Brewer NT and Fazekas KI. (2007). Predictors of HPV vaccine acceptability: A theory-informed, systematic review. Preventive Medicine, 45(2), 107–114.

Brewer NT, Gottlieb SL, Reiter PL, McRee AL, Liddon N, Markowitz L and Smith JS. (2011). Longitudinal predictors of HPV vaccine initiation among adolescent girls in a high-risk geographic area. Sexually Transmitted Diseases, 38(3), 197.

Brewer N, Ng T, McRee A and Reiter P. (2010). Men’s beliefs about HPV-related disease. Journal of Behavioral Medicine, 33(4), 274-281.

Bryan JT. (2007). Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine, 25(16), 3001–3006.

Bryman A. (2006). Integrating quantitative and qualitative research: How is it done? Qualitative Research, 6(1), 97–113.

Bundy DG, Persing NM, Solomon BS, King TM, Murakami P, Thompson RE and Miller MR. (2013). The Improve Project: Leveraging electronic health record data to promote immunization delivery. Acad Pediatr, 13(5), 458-465.

Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M and Kim JJ. (2012). Modeling preventative strategies against HPV-related disease in developed countries. Vaccine, 30(5), F157-F167.

Carlos RC, Dempsey AF, Resnicow K, Ruffin M, Patel DA, Straus CM and Dalton VK. (2011). Maternal characteristics that predict a preference for mandatory adolescent HPV vaccination. Human Vaccines, 7(2), 225-229.

Caskey R, Lindau ST and Alexander GC. (2009). Knowledge and early adoption of the HPV vaccine among girls and young women: Results of a national survey. Journal of Adolescent Health, 45(5), 453–462.

Centers for Disease Control and Prevention. (2010). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report.

Chan SS, Cheung TH, Lo WK and Chung TK. (2007). Women's attitudes on human papillomavirus vaccination to their daughters. Adolescent Health, 41(2), 204-7.

Charo A. (2007). Politics, parents, and prophylaxis: Mandating HPV vaccination in the United States. The New England Journal of Medicine, 356(19), 1905–1908.

Chesson W, Blandford M, Gift L, Tao G and Irwin L. (2004). The estimated direct medical costs of sexually transmitted diseases among American youth, 2000. Perspectives on Sexual and Reproductive Health, 36(1), 11–19.

Chesson HW, Ekwueme DU, Saraiya M and Markowitz LE. (2008). Cost-effectiveness of Human Papillomavirus Vaccination in the United States. Emerging Infectious Diseases, 14(2), 244-251.

Cover JK, Nghi NQ, LaMontagne DS, Huyen DTT, Hien NT and Nga LT. (2012). Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. BMC Public Health, 12(629).

Crosignani P, Stefani AD, Fara GM, Isidori AM, Lenzi A, Liverani CA, Lombardi A, Mennini FS, Palu G, Pecorelli S, Paracino AP, Signorelli C and Zuccotti GV. (2013).Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health, 13(642).

Daley EM, Marhefka S, Buhi E, Hernandez ND, Chandler R, Vamos C, Kolar S, Wheldonz C, Papenfuss MR and Giuliano AR. (2011). Ethnic and Racial Differences in HPV knowledge and vaccine intentions among men receiving HPV test results. Vaccine, 29(23), 4013-4018.

Dempsey AF and Davis MM. (2006). Overcoming barriers to adherence to HPV vaccination recommendations. Am J Manag Care, 12(17 Suppl), S484-91.

Dempsey F, Koutsky A and Golden M. (2007). Potential impact of Human Papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases. Sexually Transmitted Diseases, 34(7), 503–507.

Dunne EF, Markowitz LE, Saraiya M, Stokley S, Middleman A, Unger ER and Iskander J. (2014). CDC Grand Rounds: Reducing the burden of HPV-associated cancer and disease. MMWR: Morbidity & Mortality Weekly Report, 63(4), 69-72.

Dunne EF, Sternberg M, Markowitz LE, McQuillan G, Swan D, Patel S and Unger ER. (2011). Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States—National Health and Nutrition Examination Survey, 2003–2006: opportunity to measure HPV vaccine impact? Journal of Infectious Diseases, 204(4), 562–565.

Ellenberg SS. (2012). Protecting clinical trial participants and protecting data integrity: Are we meeting the challenges? PLoS Medicine, 9(6), e1001234.

Emam KE, Mercer J, Moreau K, Grava-Gubins I, Buckeridge D and Jonker E. (2011).Physician privacy concerns when disclosing patient data for public health purposes during a pandemic influenza outbreak. BMC Public Health, 11(454).